In a recent ESCEND study we have shown that near-infrared fluorescence molecular endoscopy (NIR-FME) using the tracer cetuximab-800CW can strongly improve the detection of dysplastic lesions missed by HD-white light endoscopy (WLE). NIR-FME visualized all 12 HD-WLE visible lesions and 5 HD-WLE invisible dysplastic lesions. This makes our ESCEND technology a game-changer in the screening and surgery of esophageal cancer.
The study was published in the Journal of Nuclear Medicine (click on the image)